April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Safety Testing of Epimacular Brachytherapy using Microperimetry
Author Affiliations & Notes
  • Robert Petrarca
    Ophthalmology, King's College Hospital NHS Foundation Trust, London, United Kingdom
  • Matthew Richardson
    Ophthalmology, King's College Hospital NHS Foundation Trust, London, United Kingdom
  • Jeffrey A. Nau
    Clinical Affairs, NeoVista Inc, Newark, Arizona
  • Timothy L. Jackson
    Ophthalmology, King's College Hospital NHS Foundation Trust, London, United Kingdom
  • Footnotes
    Commercial Relationships  Robert Petrarca, NeoVista Inc (R); Matthew Richardson, None; Jeffrey A. Nau, NeoVista Inc (E); Timothy L. Jackson, NeoVista Inc (F, R)
  • Footnotes
    Support  Research Grant: NeoVista Inc
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1680. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robert Petrarca, Matthew Richardson, Jeffrey A. Nau, Timothy L. Jackson; Safety Testing of Epimacular Brachytherapy using Microperimetry. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1680.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To test retinal sensitivity in patients undergoing epimacular brachytherapy for previously treated neovascular age-related macular degeneration (nAMD).

Methods: : A prospective study of 12 subjects enrolled on the MERITAGE study at one UK site. At baseline, subjects underwent pars plana vitrectomy and 24 Gray epimacular brachytherapy using a Strontium-90 source (NeoVista, Newark, CA). Patients received ranibizumab therapy monthly if predefined retreatment criteria were met. Microperimetry (MP-1; Nidek Technologies, Padova, Italy) was performed pre-operatively and at month 12.

Results: : Mean age was 75 (SD 8) years. ETDRS VA remained stable over 12 months (-0.33 letters; SD 13.2; P=0.932) with a mean of 3.5 ranibizumab injections, including those given at baseline for pre-existing disease activity. Both mean sensitivity (MS) and mean defect improved slightly by 0.79 dB (SD, 3.92 dB; P=0.499) and 1.71 dB (SD, 4.26 dB; P=0.192) respectively. The increase in MS was evident both within the treated lesions (0.88 dB; SD 3.17; P=0.357), and in neighbouring unaffected retina (0.65 dB; SD 4.23; P=0.606), as defined using fluorescein angiography and fundus photographs. Fixation stability and location were unaffected.

Conclusions: : The fact that retinal sensitivity remained stable in areas not visibly affected by nAMD suggests that epimacular brachytherapy does not produce a deleterious effect in healthy retina.

Clinical Trial: : http://www.clinicaltrials.gov NCT00809419

Keywords: age-related macular degeneration • radiation therapy • lesion study 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.